Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.
Open Forum Infect Dis
; 9(9): ofac448, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-2051511
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may present risk to patients treated with donor-derived microbiome therapies when appropriate manufacturing controls and inactivation processes are lacking. We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
Open Forum Infect Dis
Year:
2022
Document Type:
Article
Affiliation country:
Ofid
Similar
MEDLINE
...
LILACS
LIS